Phenylimidazolidines having antiandrogenic activity
Patent 5627201 Issued on May 6, 1997. Estimated Expiration Date: 
January 13, 2015. Estimated Expiration Date is calculated based on simple USPTO term provisions. It does not account for terminal disclaimers, term adjustments, failure to pay maintenance fees, or other factors which might affect the term of a patent.
January 13, 2015. Estimated Expiration Date is calculated based on simple USPTO term provisions. It does not account for terminal disclaimers, term adjustments, failure to pay maintenance fees, or other factors which might affect the term of a patent.Patent References 3668217 3798233 3846441 Antiandrogenic and schistosomicidal imidazolidine derivatives N-(2-Fluoro-4-halo-5-substituted phenyl) hydantoins Herbicidal 5-substituted-3-phenyl-imidazolidine-2,4-diones Process for 1-phenyl-imidazoline-2,5-diones Patent #: 5166358 InventorsAssigneeApplicationNo. 372648 filed on 01/13/1995US Classes:514/386, Divalent chalcogen or acyclic nitrogen double bonded directly to ring carbon of the diazole ring, or tautomeric equivalent514/342, Ring sulfur in the additional hetero ring514/391, Benzene ring bonded directly to the diazole ring by nonionic bonding548/311.1, Additional hetero ring attached directly or indirectly to the diazole ring by nonionic bonding (e.g., 1,3-dioxolan-2-yl methyl-imidazole, etc.)548/317.1, Plural chalcogens bonded directly to ring carbons of the diazole ring548/318.5, Having -C(=X)-, wherein X is chalcogen, bonded directly to the diazole ring548/320.1, Nitrogen attached indirectly to the diazole ring by acyclic nonionic bonding548/320.5, Halogen attached directly or indirectly to the diazole ring by acyclic nonionic bonding548/321.1Benzene ring bonded directly to the diazole ringExaminersPrimary: Higel, Floyd D.Attorney, Agent or FirmInternational ClassesA61K 031/415C07D 233/72 Foreign Application Priority Data1991-01-09 FRAbstractA compound of the formula ##STR1## wherein R1 is selected from the group consisting of --CN, --NO2 and halogen, R2 is --CF3 or halogen, --A--B-- is selected from the group consisting of ##STR2## X is --O-- or --S--, R3 is selected from the group consisting of hydrogen, alkyl, alkenyl and alkynyl of up to 12 carbon atoms, aryl and aralkyl of up to 12 carbon atoms, all optionally substituted with at least one member of the group consisting of --OH, halogen, --SH, --CN, acyl and acyloxy of up to 7 carbon atoms, --aryl, --O--aryl, --O--aralkyl --S-- aryl of up to 12 carbon atoms the aryl and aralkyl being optionally substituted with a member of the group consisting of halogen, --CF3, alkyl, alkoxy, alkenyl, alkenyloxy, alkynyl and alkynyloxy with the sulfur being optionally oxidized to sulfone or sulfoxide, free, esterified, amidified or salified carboxy, --NH2, mono and dialkylamino and heterocyclic of 3 to 6 ring members and containing at least one heteroatom selected from the group consisting of oxygen, sulfur and nitrogen, the alkyl, alkenyl and alkynyl being optionally interrupted with at least one member of the group consisting of oxygen, nitrogen and sulfur optionally oxidized to sulfoxide or sulfone, trialkylsilyl with the alkyl having 1 to 6 carbon atoms and acyl and acyloxy of an organic carboxylic acid of 1 to 7 carbon atoms and Y is --O--, --S-- or --NH--, except the compounds wherein --A--B-- is ##STR3## X is oxygen, R3 is hydrogen and Y is oxygen or --NH--, R2 is --CF3 or halogen and R1 is --NO2 or halogen and their non-toxic, pharmaceutically acceptable acid addition salts.Field of SearchPlural chalcogens bonded directly to ring carbons of the diazole ringHalogen attached directly or indirectly to the diazole ring by acyclic nonionic bonding Divalent chalcogen or acyclic nitrogen double bonded directly to ring carbon of the diazole ring, or tautomeric equivalent Benzene ring bonded directly to the diazole ring by nonionic bonding Ring sulfur in the additional hetero ring |
| ||||||||||||||
